drugset / Trial / NCT01440595
Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered concomitantly with peg-interferon alfa-2b (Peg-IFN) and ribavirin (RBV) to treatment-naïve participants with chronic genotype 2 (GT2) or genotype 3 (GT3) hepatitis C virus (HCV) infections.
Timeline
- Start
- 2011-11-28
- Primary completion
- 2012-05-01
- Completion
- 2012-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GRAZOPREVIR ANHYDROUS | Small molecule | 200 mg | — |
| Subject | GRAZOPREVIR ANHYDROUS | Small molecule | 400 mg | — |
| Subject | GRAZOPREVIR ANHYDROUS | Small molecule | 800 mg | — |
| Background | Peginterferon alfa-2b | Protein / enzyme biologic | 1.5 ug/kg | Subcutaneous |
| Background | Ribavirin | Small molecule | 600 mg | — |
| Background | Ribavirin | Small molecule | 1400 mg | — |